Business Wire

SUNTEC-GROUP

9.12.2021 06:26:14 CET | Business Wire | Pressemeddelelse

Del
SEB, Nordens førende erhvervsbank, vælger SunTecs pakke med løsninger til en koncernomspændende udrulning for at automatisere næste generation af tilbud til fakturering-programmet

SunTec Business Solutions, verdens førende prisfastsættelses- og faktureringsvirksomhed, meddelte i dag, at virksomheden er blevet valgt af Nordens førende erhvervsbank, SEB, til en koncernomspændende global udrulning og til at automatisere deres næste generation af tilbud-til-fakturering-program. SunTecs pakke med løsninger vil digitalisere bankens salgsproces, fra aftalehåndtering og prisfastsættelse til fakturering.

SEB valgte SunTec som teknologipartner til at hjælpe med at opfylde deres vigtigste strategiske initiativer for at blive førende inden for kundeoplevelser, skabe robusthed og fleksibilitet i banken og øge aktiviteterne for store erhvervs- og finansinstitutioner samt SMV'er.

Olle Durelius, Co-Head Transaction Services hos SEB, fortæller, "Vores ambition er at opgradere vores eksisterende processer, og vi er meget glade for at have indgået et partnerskab med SunTec og starter denne rejse for at forbedre og fremme digitalisering og automatisering. Vi var på udkig efter en løsningsudbyder, der kunne understøtte transformationen af vores aktiviteter. I SunTec fandt vi en ligesindet partner, der kunne hjælpe os med at digitalisere vores salgsproces, sikre hurtigere time-to-market, stoppe indtægtslækager, reducere manuel indgriben og sikre, at vi fakturerer klienterne i overensstemmelse med deres forventninger. Med SunTecs pakke med løsninger og platformen Xelerate vil vi understøtte vores aktiviteter inden for likviditetsstyring samt globale depotydelser og "sub-custody" til en start."

Nanda Kumar, grundlægger og CEO hos SunTec, udtaler, "Vi er meget glade for at have indgået et partnerskab med SEB for at styrke deres position som rådgiver til erhvervsklienter, forbedre driftsmæssig fortræffelighed og sikre digital distribution af deres tilbud. Vores robuste pakke med løsninger udrullet på vores Xelerate-platform vil tilbyde en teknologisk infrastruktur, der er API-venlig, modulopbygget af natur, og som automatiserer deres tilbud til fakturering-livscyklus. Denne aftale er en milepæl for os i Norden og viser, at banker i stigende grad skal gå mod en arkitektur i tre lag og udnytte et intelligent midterlag for at sikre agilitet og kundecentrering."

Om SunTec

SunTec er verdens førende prisfastsættelses- og faktureringsvirksomhed, der skaber værdi for virksomheder via cloudbaserede produkter. Mere end 130 klienter i over 45 lande stoler på, at SunTec kan levere meget personligt tilpassede produkter, tilbud, prisfastsættelse, loyalitetsprogrammer og fakturering for mere end 400 millioner slutkunder. SunTecs produkter er baseret på vores cloud-native og cloud-agnostiske, API first, mikrotjenestebaserede proprietære platform, Xelerate, og leveres på stedet, på privat cloud og som SaaS. SunTec har globale aktiviteter, der omfatter USA, Storbritannien, Tyskland, Forenede Arabiske Emirater, Singapore, Canada, Australien og Indien. Besøg www.suntecgroup.com for at få flere oplysninger, eller send en e-mail til os på marketing@suntecgroup.com .

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 08:30:00 CEST | Press release

Approval based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years Second approval for Enhertu in the EU in two months Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results fro

Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 20261.9.2026 08:30:00 CEST | Press release

Following the success of the Maison's Fall-Winter 2025 and Spring-Summer 2026 campaigns, KARL LAGERFELD is delighted to announce the extension of its relationship with global entrepreneur, media personality and cultural icon Paris Hilton, continuing a partnership that has resonated with audiences around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831566835/en/ KARL LAGERFELD - Paris Hilton ©Matt Easton As the face of the Maison through Fall-Winter 2026 and Spring-Summer 2027, Paris Hilton returns for the next chapter of KARL LAGERFELD's From Paris With Love story, continuing to bring her signature confidence, wit and individuality. Photographed for the first time by Matt Easton, the Fall-Winter 2026 campaign introduces a new dimension to the narrative while remaining true to the House's established codes. At the heart of the Fall-Winter 2026 story, two masters of self-reinvention meet. Making his debut is NO

Flashnet Partners with Netmore in Strategic Global Partnership for Smart Street Lighting1.9.2026 08:00:00 CEST | Press release

Collaboration combines carrier-grade LoRaWAN® connectivity with award-winning smart street lighting technology to accelerate smart city transformation Netmore Group, the leading network operator and platform provider for Massive IoT, today announced that Flashnet, a Lucy Group company and global leader in intelligent street lighting solutions, has joined Netmore's Pulse Partner Program. The partnership marks another important milestone in Netmore's growing ecosystem, combining best-in-class connectivity with proven smart infrastructure solutions to accelerate the digital transformation of cities and utilities around the world. Driven by rapid urbanisation, government sustainability mandates, and the accelerating rollout of smart city programs worldwide, smart street lighting is increasingly recognized as the entry point for smart city transformation and one of the fastest-growing segments of the global IoT infrastructure market. As municipalities and utilities continue to modernize cri

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release

Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye